Headquartered in Palo Alto, California, Eiger BioPharmaceuticals has established itself as a prominent commercial-stage biopharmaceutical company that specializes in developing and commercializing targeted therapies for rare and ultra-rare diseases both in the United States and abroad. The firm's lead product candidate, Lonafarnib, is a highly innovative, orally bioavailable, small molecule that is currently in Phase III clinical trials aimed at curing hepatitis delta virus infection. In addition to Lonafarnib, Eiger BioPharmaceuticals has brought Lambda, which has accomplished Phase II clinical trials and targets type III interferon receptors; Lonafarnib as a treatment for progeria and progeroid laminopathies; and Avexitide, which also has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Since its establishment in 2008, Eiger BioPharmaceuticals has consistently demonstrated its commitment to improving the lives of people grappling with rare and ultra-rare diseases.
Eiger BioPharmaceuticals's ticker is EIGR
The company's shares trade on the NASDAQ stock exchange
They are based in Palo Alto, California
There are 11-50 employees working at Eiger BioPharmaceuticals
It is eigerbio.com
Eiger BioPharmaceuticals is in the Healthcare sector
Eiger BioPharmaceuticals is in the Biotechnology industry
The following five companies are Eiger BioPharmaceuticals's industry peers: